The Jewish General Hospital Cell Processing Centre is designed as an enabling infrastructure to support the prosecution of early phase clinical trials of cell-based therapies where processing of human cell and tissue is required as part of the study. The objective of this facility is to render accessible to the patient community cutting edge, experimental cellular pharmaceuticals for treatment of human catastrophic illnesses. It promotes development of technologies from institutional scientists as well as partnership development of technologies from other biomedical institutions, academic networks, biotechnology firms and pharmaceutical industry. The JGH CPC’s successful development is optimized within an environment of cooperation on a regional and national scale. The JGH CPC is part of the McGill family of enabling infrastructures and has established links with many Quebec-based Medical Schools.
The JGH CPC has experience in the preparation of patient cells for clinical translation of cell and gene therapies within the JGH, such as was done for the first patient in Quebec to receive gene-enhanced progenitor cells in a phase I trial for pulmonary hypertension (study results of all patients published in the Circulation Research Journal in 2015). The JGH CPC can similarly be involved in the translation of other successful preclinical cell and gene therapy research, such as that of our own preclinical laboratories at the Lady Davis Institute, JGH and of others at McGill University and elsewhere in Canada.
The JGH CPC is currently receiving infrastructure support from ThéCell, the FRQS-funded Cell, Tissue and Gene Therapy Network of Quebec.
Dr. Nicoletta Eliopoulos, Director
Jewish General Hospital
3755, chemin de la Côte-Sainte-Catherine
Montreal, Quebec, Canada
Tel.: 514 340 8222 ext. 22757
neliopou [at] jgh.mcgill.ca (Email)